Top Companies in Microsampling Devices Market

The at-home blood collection devices market is projected to reach USD 135.0 million by 2029 from an estimated USD 93.5 million in 2024, at a CAGR of 7.6% during the forecast period. Increasing infectious disease bioburden and progressing lifestyle disorders in most parts of the world have increased the demand for accurate and faster home blood collection tools, thus feeding the growth of the at-home blood collection devices market.

The increasing geriatric population and rising prevalence of age-related health ailments are also responsible for the escalating demand for capillary blood collection devices. Older people are more prone to have chronic diseases such as diabetes, hypertension, and infections like hepatitis, and so having a readily available and easy means of blood sample collection at home is becoming imperative. They present a convenient solution for older people who can find it difficult to visit healthcare centers on a regular basis, enabling them to monitor their health more independently and safely at home.

To know about the assumptions considered for the study download the pdf brochure

The increasing popularity of pain-free devices and constant technological innovation are further propelling the demand for home blood sample collection devices. More and more individuals prefer easy, least-invasive solutions, so the needle-free as well as the laser-based technologies are gaining significant traction. All these technologies cause less pain and stress related with the conventional blood tests, giving a better user experience. Besides, innovations in microsampling is also making these devices precise and easy to use. As more individuals are turning towards remote health monitoring and self-diagnosis, the market is growing to cater to the increasing demand for easy access to at-home sample collection solutions.

The key players in this market are Trajan Group Holdings Limited (Australia), Tasso, Inc. (US), YourBio Health, Inc. (US), A. Menarini Diagnostics s.r.l (Italy), R-Biopharm AG (Germany), Sussex Pathology Limited (UK), ImmunoServ (UK), Labonovum (Netherlands), Alpha Laboratories (UK), Lipomic Healthcare (India), Tri-Tech Forensics (US), RDA Spot Inc (Lithuania), Spot On Sciences (US), Capitainer (Sweden), PanoHealth (US), Lameditech (South Korea), Sara Healthcare (India), Owen Mumford Ltd (UK), RedDrop Dx, Inc. (US), AdvaCare Pharma (US), Naulakha Industries (India), Phoenix Healthcare Solutions, LLC (US), and Drawbridge Health, Inc. (US).

In 2023, Tasso, Inc. was a leader in the market for at-home blood collection devices. The company has been a major player in large-scale pharmaceutical clinical trials since its inception and has a significant presence in many hospitals in the US. The reasons for the success of Tasso stem from both organic and inorganic growth strategies. Through the achievement of necessary regulatory approvals and strategic alliances, the company has not only increased product offerings but has also strengthened its position in the market. All this has been important in enabling Tasso to sustain leadership and expand in the at-home blood collection devices market.

In 2023, Trajan Group Holdings Limited held a significant share in the at-home blood collection devices market.  The company operates seven manufacturing plants in the US, Australia, Europe, and Malaysia, in addition to other plants in Australia, the US, Asia, and Europe.   In order to further boost its presence in the market, Trajan has been intensively seeking strategic partnerships and collaborations. In January 2024, CliniSciences entered an agreement with Trajan to distribute its Neoteryx microsampling solutions. Such strategic moves are likely to increase the company's market presence and enable it to maintain market growth.

YourBio Health, Inc. is one of the key players in the at-home blood collection devices market, expanding patient access to diagnostics and health monitoring, especially for patients with restricted access to healthcare centers. The company specializes in creating solutions that are easy to use and promote improved patient comfort and compliance. In an effort to solidify its market leadership, YourBio Health emphasizes on organic growth strategies. For example, in October 2023, the company received additional regulatory clearance for its TAP Micro Select blood collection device with certification for CE Marking. Furthermore, in April 2023, the company got 510(k) Medical Device clearance from US Food and Drug Administration (FDA) for TAP Micro Select. Through its focus on regulatory compliance, YourBio Health is poised to increase its market reach with quality, innovative health solutions that conform to industry standards.

Related Reports:

At-Home Blood Collection Devices Market by Product (Lancets, DBS Kits), Sample Type (Liquid, Dried), Collection Method (Push-button, Laser), Device Type (Self, Professional), Application (Diagnostics, Screening, Clinical Trials) - Global Forecast to 2029

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com